Key Trends Fueling the Boom in Genetic Testing

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Connecting the Dots: Gene to Disease
  • Genetic Variation Is Key to Novel Developments
  • Potential to Address Broader Unmet Needs
• Individualizing Personal Genomics.
• Rekindling Pharmacogenomics
• Personalized Medicine as a Driver for Growth
  • Targeted Therapies and Companion Diagnostics
  • Fueling Interest in Other Therapy Areas
  • Turning Yesterday' s Failures into Today' s Personalized Medicine Success Stories
    • Bucindolol
    • Vilazodone
• Creating Sustainable Growth in the Field
  • Refine Next-Generation Sequencing Technologies
  • Correctly Navigate the Approval Process
    • Amgen' s Vectibix - A Cautionary Tale
    • Pfizer' s Selzentry and Monogram Biosciences' Trofile
  • Capitalize on Recent Legislative Support
  • Effectively Engage Payers for Novel Tests
  • Push for Large-Scale Genomic Studies
  • Gracefully Ride Out the Economic Crisis
• Conclusions

Expert Commentaries

• Finding Value in Genetic Testing
• A Perspective on Approval Strategies for Gene-Based Companion Diagnostics
• Keith F. Batchelder, M.D., CEO and Founder, Genomic Health Care Strategies.

Sidebar

• Impact of the Economic Crisis on Emerging Diagnostics Companies

Tables

• 1. Select Genetic Testing Companies
• 2. Select Prenatal Diagnostic Tests for Genetic Analysis
• 3. Select Findings from Recent Genetic Variation Studies
• 4. Select Personal Genomics Services and Costs
• 5. Select Gene-Based Companion Diagnostic Tests for Breast Cancer
• 6. Targeted Therapies for Which Genetic Testing May Be Useful to Guide Prescribing
• 7. Select Genetic Companion Diagnostic Tests and Associated Therapeutics
• 8. Select Large-Scale Genetic Variation Studies

Figures

• 1. Potential Market Impact by Select Companies That Offer Novel Prenatal Diagnostics
• 2. Teams Competing for Archon X Prize for Genomics